Should patients with malignancy receive chemoprophylaxis against Pneumocystis jirovecii pneumonia?

Nat Clin Pract Oncol. 2005 Oct;2(10):490-1. doi: 10.1038/ncponc0299.

Author

Vassilios Barbounis¹

Affiliation

¹ Department of Medical Oncology, St Savas Cancer Hospital, Athens, Greece. barbouv@ath.forthnet.gr

PMID: 16205763
DOI: 10.1038/ncponc0299

No abstract available

MeSH terms

Antibiotic Prophylaxis*
Female
Follow-Up Studies
Hematologic Neoplasms / diagnosis
Hematologic Neoplasms / immunology
Humans
Immunocompromised Host / immunology*
Male
Neoplasms / diagnosis
Neoplasms / immunology*
Neoplasms / mortality
Pneumocystis carinii / isolation & purification*
Pneumonia, Pneumocystis / prevention & control*
Probability
Registries
Retrospective Studies
Risk Assessment
Survival Rate
Treatment Outcome
Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage*

Substances

Trimethoprim, Sulfamethoxazole Drug Combination